The action of hyaluronan in functional properties, morphology and expression of matrix effectors in mammary cancer cells depends on its molecular size.
CD44
breast cancer
epithelial-to-mesenchymal transition
estrogen receptors
hyaluronan
Journal
The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
24
12
2020
received:
14
09
2020
accepted:
26
01
2021
pubmed:
30
1
2021
medline:
4
8
2021
entrez:
29
1
2021
Statut:
ppublish
Résumé
Breast cancer constitutes a heterogeneous disease. The expression profiles of estrogen receptors (ERs), as well as the expression patterns of extracellular matrix (ECM) macromolecules, determine its development and progression. Hyaluronan (HA) is an ECM molecule that regulates breast cancer cells' properties in a molecular size-dependent way. Previous studies have shown that 200-kDa HA fragments modulate the functional properties, morphology, and expression of several matrix mediators of the highly metastatic ERα
Substances chimiques
Receptors, Estrogen
0
Viscosupplements
0
Hyaluronic Acid
9004-61-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4291-4310Informations de copyright
© 2021 Federation of European Biochemical Societies.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA & Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394-424.
DeSantis CE, Ma J, Goding Sauer A, Newman LA & Jemal A (2017) Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 67, 439-448.
Piperigkou Z & Karamanos NK (2020) Estrogen receptor-mediated targeting of the extracellular matrix network in cancer. Semin Cancer Biol 62, 116-124.
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10, 5367-5374.
Bouris P, Skandalis SS, Piperigkou Z, Afratis N, Karamanou K, Aletras AJ, Moustakas A, Theocharis AD & Karamanos NK (2015) Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix Biol 43, 42-60.
Chekhun S, Bezdenezhnykh N, Shvets J & Lukianova N (2013) Expression of biomarkers related to cell adhesion, metastasis and invasion of breast cancer cell lines of different molecular subtype. Exp Oncol 35, 174-179.
Gritsenko PG, Ilina O & Friedl P (2012) Interstitial guidance of cancer invasion. J Pathol 226, 185-199.
Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V et al. (2009) Breast cancer metastasis: challenges and opportunities. Cancer Res 69, 4951-4953.
Lamouille S, Subramanyam D, Blelloch R & Derynck R (2013) Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs. Curr Opin Cell Biol 25, 200-207.
Kang Y & Massagué J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118, 277-279.
Sciacovelli M & Frezza C (2017) Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer. FEBS J 284, 3132-3144.
Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2, 442-454.
Medici D, Hay ED & Olsen BR (2008) Snail and slug promote epithelial-mesenchymal transition through -catenin-T-cell factor-4-dependent expression of transforming growth factor-3. Mol Biol Cell 19, 4875-4887.
Gialeli C, Theocharis AD & Karamanos NK (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278, 16-27.
Karamanos NK, Piperigkou Z, Theocharis AD, Watanabe H, Franchi M, Baud S, Brézillon S, Götte M, Passi A, Vigetti D et al. (2018) Proteoglycan chemical diversity drives multifunctional cell regulation and therapeutics. Chem Rev 118, 9152-9232.
Karamanos NK, Theocharis AD, Neill T & Iozzo RV (2019) Matrix modeling and remodeling: a biological interplay regulating tissue homeostasis and diseases. Matrix Biol 75-76, 1-11.
Pickup MW, Mouw JK & Weaver VM (2014) The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 15, 1243-1253.
Theocharis AD, Manou D & Karamanos NK (2019) The extracellular matrix as a multitasking player in disease. FEBS J 286, 2830-2869.
Theocharis AD, Skandalis SS, Gialeli C & Karamanos NK (2016) Extracellular matrix structure. Adv Drug Deliv Rev 97, 4-27.
Garantziotis S & Savani RC (2019) Hyaluronan biology: a complex balancing act of structure, function, location and context. Matrix Biol 78-79, 1-10.
Passi A, Vigetti D, Buraschi S & Iozzo RV (2019) Dissecting the role of hyaluronan synthases in the tumor microenvironment. FEBS J 286, 2937-2949.
Heldin P, Lin CY, Kolliopoulos C, Chen YH & Skandalis SS (2018) Regulation of hyaluronan biosynthesis and clinical impact of excessive hyaluronan production. Matrix Biol 78-79, 100-117.
Karousou E, D'Angelo ML, Kouvidi K, Vigetti D, Viola M, Nikitovic D, De Luca G & Passi A (2014) Collagen VI and hyaluronan: the common role in breast cancer. Biomed Res Int 2014, 131-141. https://doi.org/10.1155/2014/606458
Vigetti D & Passi A (2014) Hyaluronan synthases posttranslational regulation in cancer. Adv Cancer Res 123, 95-119.
Velesiotis C, Vasileiou S & Vynios DH (2019) A guide to hyaluronan and related enzymes in breast cancer: biological significance and diagnostic value. FEBS J 286, 3057-3074.
Kolliopoulos C, Lin CY, Heldin CH, Moustakas A & Heldin P (2018) Has2 natural antisense RNA and Hmga2 promote Has2 expression during TGFβ-induced EMT in breast cancer. Matrix Biol 80, 29-45.
Tammi MI, Oikari S, Pasonen-Seppänen S, Rilla K, Auvinen P & Tammi RH (2018) Activated hyaluronan metabolism in the tumor matrix - causes and consequences. Matrix Biol 79, 147-164.
Vigetti D, Karousou E, Viola M, Deleonibus S, De Luca G & Passi A (2014) Hyaluronan: biosynthesis and signaling. Biochim Biophys Acta 1840, 2452-2459.
Skandalis SS, Karalis TT, Chatzopoulos A & Karamanos NK (2019) Hyaluronan-CD44 axis orchestrates cancer stem cell functions. Cell Signal 63, 109377.
Ouhtit A, Rizeq B, Saleh HA, Rahman MDM & Zayed H (2018) Novel CD44-downstream signaling pathways mediating breast tumor invasion. Int J Biol Sci 14, 1782-1790.
Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR & Ghatak S (2011) Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 278, 1429-1443.
Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, McCarthy JB, Bissell MJ, Koropatnick J & Turley EA (2007) The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 282, 16667-16680.
Knudson CB & Knudson W (2001) Cartilage proteoglycans. Semin Cell Dev Biol 12, 69-78.
Holmes MW, Bayliss MT & Muir H (1988) Hyaluronic acid in human articular cartilage. Age-related changes in content and size. Biochem J 250, 435-441.
Astachov L, Vago R, Aviv M & Nevo Z (2011) Hyaluronan and mesenchymal stem cells: from germ layer to cartilage and bone. Front Biosci (Landmark Ed) 16, 261-276.
Tammi R, Agren UM, Tuhkanen AL & Tammi M (1994) Hyaluronan metabolism in skin. Prog Histochem Cytochem 29, 1-81.
Yuan H, Amin R, Ye X, de la Motte CA & Cowman MK (2015) Determination of hyaluronan molecular mass distribution in human breast milk. Anal Biochem 474, 78-88.
Pogrel MA, Low MA & Stern R (2003) Hyaluronan (hyaluronic acid) and its regulation in human saliva by hyaluronidase and its inhibitors. J Oral Sci 45, 85-91.
Franzmann EJ, Schroeder GL, Goodwin WJ, Weed DT, Fisher P & Lokeshwar VB (2003) Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer 106, 438-445.
Lokeshwar VB, Obek C, Soloway MS & Block NL (1997) Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 57, 773-777.
Cowman MK, Lee H-G, Schwertfeger KL, McCarthy JB & Turley EA (2015) The content and size of hyaluronan in biological fluids and tissues. Front Immunol 6, 261.
Tavianatou AG, Caon I, Franchi M, Piperigkou Z, Galesso D & Karamanos NK (2019) Hyaluronan: molecular size-dependent signaling and biological functions in inflammation and cancer. FEBS J 286, 2883-2908.
Bohaumilitzky L, Huber A-K, Stork EM, Wengert S, Woelfl F & Boehm H (2017) A trickster in disguise: hyaluronan's ambivalent roles in the matrix. Front Oncol 7, 242.
Liu M, Tolg C & Turley E (2019) Dissecting the dual nature of hyaluronan in the tumor microenvironment. Front Immunol 10, 947.
Cyphert JM, Trempus CS & Garantziotis S (2015) Size matters: molecular weight specificity of hyaluronan effects in cell biology. Int J Cell Biol 2015, 67-74. https://doi.org/10.1155/2015/563818
Zhao YF, Qiao SP, Shi SL, Yao LF, Hou XL, Li CF, Lin FH, Guo K, Acharya A, Chen XB, Nie Y & Tian WM (2017) Modulating three-dimensional microenvironment with hyaluronan of different molecular weights alters breast cancer cell invasion behavior. ACS Appl Mater Interfaces 9, 9327-9338.
Stern R, Asari AA & Sugahara KN (2006) Hyaluronan fragments: an information-rich system. Eur J Cell Biol 85, 699-715.
Hosono K, Nishida Y, Knudson W, Knudson CB, Naruse T, Suzuki Y & Ishiguro N (2007) Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am J Pathol 171, 274-286.
Urakawa H, Nishida Y, Knudson W, Knudson CB, Arai E, Kozawa E, Futamura N, Wasa J & Ishiguro N (2012) Therapeutic potential of hyaluronan oligosaccharides for bone metastasis of breast cancer. J Orthop Res 30, 662-672.
Ghatak S, Misra S & Toole BP (2002) Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 277, 38013-38020.
Ghatak S, Misra S & Toole BP (2005) Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 280, 8875-8883.
Toole BP, Ghatak S & Misra S (2008) Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr Pharm Biotechnol 9, 249-252.
Tavianatou A-G, Piperigkou Z, Barbera C, Beninatto R, Masola V, Caon I, Onisto M, Franchi M, Galesso D & Karamanos NK (2019) Molecular size-dependent specificity of hyaluronan on functional properties, morphology and matrix composition of mammary cancer cells. Matrix Biol Plus 3, 100008.
Slomiany MG, Dai L, Bomar PA, Knackstedt TJ, Kranc DA, Tolliver L, Maria BL & Toole BP (2009) Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res 69, 4992-4998.
Slomiany MG, Dai L, Tolliver LB, Grass GD, Zeng Y & Toole BP (2009) Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clin Cancer Res 15, 7593-7601.
Ward JA, Huang L, Guo H, Ghatak S & Toole BP (2003) Perturbation of hyaluronan interactions inhibits malignant properties of glioma cells. Am J Pathol 162, 1403-1409.
Piperigkou Z, Bouris P, Onisto M, Franchi M, Kletsas D, Theocharis AD & Karamanos NK (2016) Estrogen receptor beta modulates breast cancer cells functional properties, signaling and expression of matrix molecules. Matrix Biol 56, 4-23.
Paterson EK & Courtneidge SA (2018) Invadosomes are coming: new insights into function and disease relevance. FEBS J 285, 8-27.
Arjonen A, Kaukonen R & Ivaska J (2011) Filopodia and adhesion in cancer cell motility. Cell Adh Migr 5, 421-430.
Knecht DA, Xue F & Janzen DM (2010) Contribution of filopodia to cell migration: a mechanical link between protrusion and contraction. Int J Cell Biol 2010, 1-13. https://doi.org/10.1155/2010/507821.
Jacquemet G, Hamidi H & Ivaska J (2015) Filopodia in cell adhesion, 3D migration and cancer cell invasion. Curr Opin Cell Biol 36, 23-31.
Clark AG & Vignjevic DM (2015) Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol 36, 13-22.
Machesky LM (2008) Lamellipodia and filopodia in metastasis and invasion. FEBS Lett 582, 2102-2111.
Franchi M, Piperigkou Z, Riti E, Masola V, Onisto M & Karamanos NK (2020) Long filopodia and tunneling nanotubes define new phenotypes of breast cancer cells in 3D cultures. Matrix Biol Plus, 6-7. https://doi.org/10.1016/j.mbplus.2020.100026
Heusermann W, Hean J, Trojer D, Steib E, von Bueren S, Graff-Meyer A, Genoud C, Martin K, Pizzato N, Voshol J et al. (2016) Exosomes surf on filopodia to enter cells at endocytic hot spots, traffic within endosomes, and are targeted to the ER. J Cell Biol 213, 173-184.
Franchi M, Piperigkou Z, Karamanos KA, Franchi L & Masola V (2020) Extracellular matrix-mediated breast cancer cells morphological alterations, invasiveness, and microvesicles/exosomes release. Cells 9. https://doi.org/10.3390/cells9092031
Chang G, Wang J, Zhang H, Zhang Y, Wang C, Xu H, Zhang H, Lin Y, Ma L, Li Q et al. (2014) CD44 targets Na + /H + exchanger 1 to mediate MDA-MB-231 cells' metastasis via the regulation of ERK1/2. Br J Cancer 110, 916-927.
Bourguignon LYW (2001) CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J Mammary Gland Biol Neoplasia 6, 287-297.
Kuo YC, Su CH, Liu CY, Chen TH, Chen CP & Wang HS (2009) Transforming growth factor-β induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type 1-matrix metalloproteinase. Int J Cancer 124, 2568-2576.
Udabage L, Brownlee GR, Nilsson SK & Brown TJ (2005) The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 310, 205-217.
Heldin P, Basu K, Olofsson B, Porsch H, Kozlova I & Kahata K (2013) Deregulation of hyaluronan synthesis, degradation and binding promotes breast cancer. J Biochem 154, 395-408.
Lien HC, Lee YH, Jeng YM, Lin CH, Lu YS & Yao YT (2014) Differential expression of hyaluronan synthase 2 in breast carcinoma and its biological significance. Histopathology 65, 328-339.
Li P, Xiang T, Li H, Li Q, Yang B, Huang J, Zhang X, Shi Y, Tan J & Ren G (2015) Hyaluronan synthase 2 overexpression is correlated with the tumorigenesis and metastasis of human breast cancer. Int J Clin Exp Pathol 8, 12101-12114.
Okuda H, Kobayashi A, Xia B, Watabe M, Pai SK, Hirota S, Xing F, Liu W, Pandey PR, Fukuda K et al. (2012) Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res 72, 537-547.
Bernert B, Porsch H & Heldin P (2011) Hyaluronan synthase 2 (HAS2) promotes breast cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1). J Biol Chem 286, 42349-42359.
Zoltan-Jones A, Huang L, Ghatak S & Toole BP (2003) Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem 278, 45801-45810.
Li Y, Li L, Brown TJ & Heldin P (2007) Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int J Cancer 120, 2557-2567.
Karalis TT, Heldin P, Vynios DH, Neill T, Buraschi S, Iozzo RV, Karamanos NK & Skandalis SS (2018) Tumor-suppressive functions of 4-MU on breast cancer cells of different ER status: regulation of hyaluronan/HAS2/CD44 and specific matrix effectors. Matrix Biol 78-79, 118-138.
Udabage L, Brownlee GR, Waltham M, Blick T, Walker EC, Heldin P, Nilsson SK, Thompson EW & Brown TJ (2005) Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res 65, 6139-6150.
Vigetti D, Deleonibus S, Moretto P, Bowen T, Fischer JW, Grandoch M, Oberhuber A, Love DC, Hanover JA, Cinquetti R et al. (2014) Natural antisense transcript for hyaluronan synthase 2 (HAS2-AS1) induces transcription of HAS2 via protein O-GlcNAcylation. J Biol Chem 289, 28816-28826.
Michael DR, Phillips AO, Krupa A, Martin J, Redman JE, Altaher A, Neville RD, Webber J, Kim MY & Bowen T (2011) The human hyaluronan synthase 2 (HAS2) gene and its natural antisense RNA exhibit coordinated expression in the renal proximal tubular epithelial cell. J Biol Chem 286, 19523-19532.
Vigetti D, Viola M, Karousou E, Deleonibus S, Karamanou K, De Luca G & Passi A (2014) Epigenetics in extracellular matrix remodeling and hyaluronan metabolism. FEBS J 281, 4980-4992.
Senbanjo LT & Chellaiah MA (2017) A multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol 5, 18-24. https://doi.org/10.3389/fcell.2017.00018
Misra S, Hascall VC, Markwald RR & Ghatak S (2015) Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front Immunol 6, 201.
Benson CS, Babu SD, Radhakrishna S, Selvamurugan N & Sankar BR (2013) Expression of matrix metalloproteinases in human breast cancer tissues. Dis Markers 34, 395-405.
Köhrmann A, Kammerer U, Kapp M, Dietl J & Anacker J (2009) Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 9, 1-20.
Lv Y, Zhao X, Zhu L, Li S, Xiao Q, He W & Yin L (2018) Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis. Theranostics 8, 2830-2845.
Radisky ES & Radisky DC (2015) Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Front Biosci (Landmark Ed) 20, 1144-1163.
Montgomery N, Hill A, McFarlane S, Neisen J, O'Grady A, Conlon S, Jirstrom K, Kay EW & Waugh DJJ (2012) CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity. Breast Cancer Res 14, R84.
Kim HJ, Il PC, Park BW, De LH & Jung WH (2006) Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J 47, 333-342.
Figueira RCS, Gomes LR, Neto JS, Silva FC, Silva IDCG & Sogayar MC (2009) Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 9, 1-11.
Niu J, Li XM, Wang X, Liang C, Zhang YD, Li HY, Liu FY, Sun H, Xie SQ & Fang D (2019) DKK1 inhibits breast cancer cell migration and invasion through suppression of β-catenin/MMP7 signaling pathway. Cancer Cell Int 19, 1-13.
Han B, Zhou B, Qu Y, Gao B, Xu Y, Chung S, Tanaka H, Yang W, Giuliano AE & Cui X (2018) FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer. Oncogene 37, 1399-1408.
Shao Q, Luo X, Yang D, Wang C, Cheng Q, Xiang T & Ren G (2017) Phospholipase Cδ1 suppresses cell migration and invasion of breast cancer cells by modulating KIF3A-mediated ERK1/2/β- catenin/MMP7 signalling. Oncotarget 8, 29056-29066.
Wolff C, Malinowsky K, Berg D, Schragner K, Schuster T, Walch A, Bronger H, Höfler H & Becker K-F (2011) Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis. J Pathol 223, 54-63.
Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V & Brünner N (1996) Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 14, 297-307.
Barbouri D, Afratis N, Gialeli C, Vynios DH, Theocharis AD & Karamanos NK (2014) Syndecans as modulators and potential pharmacological targets in cancer progression. Front Oncol 4, 1-11.
Woods A & Couchman JR (1994) Syndecan 4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component. Mol Biol Cell 5, 183-192.
Vicente CM, Aparecida D, Sartorio PV, Silva TD, Saad SS, Nader HB, Forones NM & Toma L (2018) Heparan sulfate proteoglycans in human colorectal cancer. Anal Cell Pathol (Amst) 2018, 56-66. https://doi.org/10.1155/2018/8389595
Lim CC, Multhaupt HAB & Couchman JR (2015) Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells. Mol Cancer 14, 1-18.
Afratis NA, Bouris P, Skandalis SS, Multhaupt HA, Couchman JR, Theocharis AD & Karamanos NK (2017) IGF-IR cooperates with ERα to inhibit breast cancer cell aggressiveness by regulating the expression and localisation of ECM molecules. Sci Rep 7, 1-12.
Theocharis AD & Karamanos NK (2017) Proteoglycans remodeling in cancer: underlying molecular mechanisms. Matrix Biol 75-76, 220-259.
Kelly T, Suva LJ, Huang Y, MacLeod V, Miao HQ, Walker RC & Sanderson RD (2005) Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res 65, 5778-5784.
Reiland J, Sanderson RD, Waguespack M, Barker SA, Long R, Carson DD & Marchetti D (2004) Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J Biol Chem 279, 8047-8055.
Purushothaman A, Hurst DR, Pisano C, Mizumoto S, Sugahara K & Sanderson RD (2011) Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem 286, 30377-30383.
Mook S, Van 't Veer LJ, Rutgers EJ, Ravdin PM, Van De Velde AO, Van Leeuwen FE, Visser O & Schmidt MK (2011) Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 103, 585-597.
Björnström L & Sjöberg M (2005) Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19, 833-842.
Yang C, Cao M, Liu H, He Y, Xu J, Du Y, Liu Y, Wang W, Cui L, Hu J et al. (2012) The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem 287, 43094-43107.
Kothapalli D, Flowers J, Xu T, Puré E & Assoian RK (2008) Differential activation of ERK and Rac mediates the proliferative and anti-proliferative effects of hyaluronan and CD44. J Biol Chem 283, 31823-31829.
Fuchs K, Hippe A, Schmaus A, Homey B, Sleeman JP & Orian-Rousseau V (2013) Opposing effects of high-and low-molecular weight hyaluronan on CXCL12-induced CXCR4 signaling depend on CD44. Cell Death Dis 4, e819.
Bourguignon LYW, Wong G, Earle C, Krueger K & Spevak CC (2010) Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem 285, 36721-36735.
Bourguignon LYW, Spevak CC, Wong G, Xia W & Gilad E (2009) Hyaluronan-CD44 interaction with protein kinase Cε promotes oncogenic signaling by the stem cell marker nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance. J Biol Chem 284, 26533-26546.
Alaniz L, Rizzo M, Malvicini M, Jaunarena J, Avella D, Atorrasagasti C, Aquino JB, Garcia M, Matar P, Silva M et al. (2009) Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response. Cancer Lett 278, 9-16.
Zeng C, Toole BP, Kinney SD, Kuo JW & Stamenkovic I (1998) Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 77, 396-401.
Slevin M, Krupinski J, Gaffney J, Matou S, West D, Delisser H, Savani RC & Kumar S (2007) Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol 26, 58-68.
Russo RIC, García MG, Alaniz L, Blanco G, Alvarez E & Hajos SE (2008) Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int J Cancer 122, 1012-1018.
Lompardía SL, Díaz M, Papademetrio DL, Mascaró M, Pibuel M, Álvarez E & Hajos SE (2016) Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of imatinib. Glycobiology 26, 343-352.
Kim GE, Lee JS, Choi YD, Lee KH, Lee JH, Nam JH, Choi C, Kim SS, Park MH, Yoon JH et al. (2014) Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer. BMC Cancer 14, 959.
Zhang Q, Liu S, Parajuli KR, Zhang W, Zhang K, Mo Z, Liu J, Chen Z, Yang S, Wang AR et al. (2017) Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene 36, 687-699.
Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, Shetuni B & Barsky SH (2010) ERα signaling through slug regulates E-cadherin and EMT. Oncogene 29, 1451-1462.
Auvinen P, Rilla K, Tumelius R, Tammi M, Sironen R, Soini Y, Kosma VM, Mannermaa A, Viikari J & Tammi R (2014) Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival. Breast Cancer Res Treat 143, 277-286.
Zhang Z, Tao D, Zhang P, Liu X, Zhang Y, Cheng J, Yuan H, Liu L & Jiang H (2016) Hyaluronan synthase 2 expressed by cancer-associated fibroblasts promotes oral cancer invasion. J Exp Clin Cancer Res 35, 181.
Draffin JE, McFarlane S, Hill A, Johnston PG & Waugh DJJ (2004) CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 64, 5702-5711.
Bourguignon LYW, Peyrollier K, Xia W & Gilad E (2008) Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283, 17635-17651.
Fan SH, Wang YY, Lu J, Zheng YL, Wu DM, Zhang ZF, Shan Q, Hu B, Li MQ & Cheng W (2015) CERS2 suppresses tumor cell invasion and is associated with decreased V-ATPase and MMP-2/MMP-9 activities in breast cancer. J Cell Biochem 116, 502-513.
Smith SM, Lyu YL & Cai L (2014) NF-κB affects proliferation and invasiveness of breast cancer cells by regulating CD44 expression. PLoS One 9, e106966.
Zhang C, Xu Y, Hao Q, Wang S, Li H, Li J, Gao Y, Li M, Li W, Xue X et al. (2015) FOXP3 suppresses breast cancer metastasis through downregulation of CD44. Int J Cancer 137, 1279-1290.
Bourguignon LYW, Gunja-Smith Z, Iida N, Zhu HB, Young LJT, Muller WJ & Cardiff RD (1998) CD44v3,8-10is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 176, 206-215.
Pfaff M, Göhring W, Brown JC & Timpl R (1994) Binding of purified collagen receptors (α1β1, α2β1) and RGD-dependent integrins to laminins and laminin fragments. Eur J Biochem 225, 975-984.
Ganguly KK, Pal S, Moulik S & Chatterjee A (2013) Integrins and metastasis. Cell Adhes Migr 7, 251-261.
Berrier AL & Yamada KM (2007) Cell-matrix adhesion. J Cell Physiol 213, 565-573.
Feoktistova M, Geserick P & Leverkus M (2016) Crystal violet assay for determining viability of cultured cells. Cold Spring Harb Protoc 4. https://doi.org/10.1101/pdb.prot087379
De Wever O, Hendrix A, De Boeck A, Westbroek W, Braems G, Emami S, Sabbah M, Gespach C & Bracke M (2010) Modeling and quantification of cancer cell invasion through collagen type I matrices. Int J Dev Biol 54, 887-896.